Spyre Therapeutics unveils clinical data on new IBD antibody therapies at UEGW 2026.

Spyre Therapeutics presented clinical and preclinical data for its three investigational antibodies—SPY001, SPY002, and SPY003—targeting inflammatory bowel disease (IBD) at the United European Gastroenterology Week 2026. These antibodies are being tested alone and in combinations in the SKYLINE Phase 2 trial, showing promise for deeper, more durable disease control compared to current treatments. The company highlighted the potential of combination therapies to improve efficacy and patient outcomes in IBD. Further combination trial results are expected next year, which could significantly advance treatment options for IBD patients.

Spyre Therapeutics shares trade at USD 79.90 on Pluang as of Oct 18, 2026, 20:41 WIB. The stock is down 0.25% in the last day, with a market cap of $7.47 billion. Trading volume is 881,422 shares, reflecting steady investor interest amid ongoing clinical developments.